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Abstract
Background: Antiplatelet therapy has proven beneficial in the treatment of cardiovascular disease.
Proton pump inhibitors (PPIs) are commonly used for gastroprotection in patients receiving
antiplatelet therapy. Several trials have been carried out to establish interactions between PPIs,
clopidogrel and soluble formulations of aspirin, but no studies with PPIs and enteric-coated (EC)
forms of aspirin have been conducted. The aim of this study was to assess if concomitant
pantoprazole usage influences antiplatelet effect of EC aspirin in patients with acute coronary
syndrome treated with percutaneous coronary intervention (PCI) and dual antiplatelet therapy.
Methods: Thirty-one consecutive patients were prospectively enrolled in the randomized,
crossover, open-labelled designed study. The first 16 patients were given orally 40 mg of
pantoprazole for the first four days while the next 15 subjects were treated with pantoprazole
from the fifth to the eighth day of hospitalisation. Blood samples were collected at 6.00 a.m.,
10.00 a.m., 2.00 p.m., and 7.00 p.m. on the fourth and eighth day of hospitalization. Aggrega-
tion in response to arachidonic acid was assessed in the whole blood on a new generation
impedance aggregometer.
Results: Lower overall platelet aggregation in patients treated with pantoprazole (p < 0.03)
was observed. When aggregation of platelets was analyzed separately at different times, the
differences reached statistical significance six hours after the administration of pantoprazole
and antiplatelet agents. The highest absolute difference in arachidonic acid-dependent aggre-
gation was observed two hours after drug ingestion.
Conclusions: Co-administration of pantoprazole may enhance the antiplatelet effect of
enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI. (Cardiol J
2009; 16, 6: 535–544)
Key words: platelet aggregation, aspirin, pantoprazole, proton pump inhibitors,
antiplatelet therapy, acute coronary syndrome
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Introduction
Acute coronary syndrome (ACS), the leading
cause of death in most European countries, occurs
as a result of thrombus formation within the coro-
nary artery lumen [1]. Coronary plaque rupture in
ACS, or that associated with percutaneous coronary
intervention (PCI), releases thrombogenic sub-
stances into the circulation, stimulating platelet
activation and aggregation [2]. As dual antiplatelet
therapy has proven beneficial in the treatment of
cardiovascular disease and decreasing the occur-
rence of stent thrombosis, current guidelines rec-
ommend a combination of aspirin and clopidogrel for
patients with ACS and/or undergoing PCI [3, 4].
Aspirin has been widely used in the primary
and secondary prevention of cardiovascular events
since many trials demonstrated its beneficial effect
[5–7]. Despite this strong evidence of aspirin’s pro-
tective effect, there is a group of patients who suf-
fer from acute coronary syndrome due to persist-
ent platelet hyperactivity. This ‘aspirin resistance’
has been reported in 5% to 40% of patients, depend-
ing on the assessment method [8–10]. A number of
clinical studies and a recent meta-analysis conduct-
ed by Krasopoulous et al. have correlated aspirin
resistance with unfavorable long-term clinical out-
comes, not only in patients with coronary artery
disease (CAD) but also in patients with ischemic
stroke or peripheral arterial disease [11–14].
Beside its enormous cardioprotective effect,
antiplatelet treatment carries substantial side
effects: mainly gastrointestinal ulceration and bleed-
ing [15]. Observational studies [16, 17], as well as
Antithrombotic Trialists’ Collaboration meta-ana-
lysis [18], have reported a two to four-fold increased
risk of upper gastrointestinal events when a low-
dose of acetylsalicylic acid (ASA) is administered.
For that reason, patients receiving a dual an-
tiplatelet therapy after coronary stenting are com-
monly treated with proton pump inhibitors for gas-
trointestinal protection. Recent guidelines pub-
lished by the American Heart Association, the
American College of Gastroenterology and the
American College of Cardiology recommend proton
pump inhibitors (PPI) therapy for the majority of
patients treated with antiplatelet agents, including
all patients aged 60 years or older and patients
receiving dual antiplatelet therapy [15]. However,
it was demonstrated that PPIs may attenuate the
antiplatelet and antipyretic effect of aspirin [19, 20]
in the rat model.
Buffered or enteric-coated preparations of ASA
are proposed as another approach to gastroprotec-
tion of patients requiring antiplatelet treatment. As
far as we know, no trial assessing the pharmaco-
logical or clinical interaction between enteric-coat-
ed forms of aspirin and proton pump inhibitors has
been conducted, while data regarding interaction
between plain aspirin and PPIs is sparse.
The aim of our study was to assess whether
concomitant pantoprazole usage influences the an-
tiplatelet effect of enteric-coated aspirin in patients
with acute coronary syndrome treated with percu-
taneous coronary intervention and dual antiplate-
let therapy.
Methods
Patients
Thirty-one consecutive patients (22 men and
nine post-menopausal women) admitted to the De-
partment of Cardiology and Internal Medicine of the
Collegium Medicum in Bydgoszcz with a diagnosis
of ACS, and designated to undergo PCI, were pro-
spectively recruited into the randomized, crosso-
ver, open-labelled study (Fig. 1).
Study design
Patients were randomized to receive low-dose
(75 mg) enteric-coated aspirin alone (16 patients)
or low-dose enteric-coated aspirin plus 40 mg pan-
toprazole (15 patients) for four days. Then partici-
pants were ‘crossed over’ to receive the alternative
treatment regime for the next four days. Trial
exclusion criteria were:
— age less than 18 years;
— clinical indication for PPI usage;
— clinical indications for prolonged use of hepa-
rin or fondaparinux;
— clinical indication for ASA or clopidogrel ma-
intaining daily dose > 75 mg;
— persistent atrial fibrillation or other indication
for oral anticoagulants;
— cardiogenic shock at admission or initiation of
the treatment with vasopressors before PCI;
— a history of chronic heart failure in functional
class III or IV of the New York Heart Associa-
tion (NYHA), or hemodynamically significant
valvular heart disease or idiopathic cardiomyo-
pathy;
— thrombocytopenia (< 100 000/mm3) or history
of congenital or acquired bleeding disorder;
— anemia with amount of hemoglobin < 10.0 g/dL;
— any symptomatic concomitant infection;
— previous history of stent thrombosis.
All participants provided informed written con-
sent before entering the study. The clinical chara-
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cteristics of the patient population are presented in
Table 1. The study protocol was approved by the
Local Ethics Committee.
Concomitant pharmacotherapy
At the first contact with health care providers
immediately after the diagnosis of ACS and deci-
sion of PCI, all patients were pretreated with an
intravenous bolus of unfractionated heparin (70 IU/
/kg, but not more than 5000 IU) and oral loading
doses of clopidogrel (600 mg) and aspirin (300 mg).
At the catheterization laboratory, a second dose of
unfractionated heparin was intra-arterially admin-
istered in a weight-adjusted manner (up to 100 IU/
/kg) or under activated clotting time guidance (to the
target range 200–250 s), if abciximab, a blocker of
platelet glycoprotein IIb/IIIa, was intended. Abcixi-
mab was given at the discretion of the invasive
cardiologist. Throughout the hospitalization, clopi-
dogrel was continued in single doses of 75 mg giv-
en at 8.00 a.m. Post-discharge antiplatelet therapy
was planned in accordance with current European
recommendations. Concomitant medications in all
patients, included ramipril and bisoprolol, were pro-
Figure 1. Study design.
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vided at 8.00 a.m. in doses adjusted for resting heart
rate and blood pressure, and atorvastatin was ad-
ministered at 8.00 p.m.
Percutaneous coronary interventions
Coronary angiography and PCI procedures
were performed using the standard technique via
the femoral artery with the aid of an Integris Allura
device (Philips, the Netherlands). Non-ionic low-
osmolar contrast media were applied. During angi-
ography, at least five left coronary artery and three
right coronary artery projections were taken after
previous administration of 0.3 mg nitroglycerine
into the coronary vessels, if arterial pressure was
sufficient. Epicardial coronary flow was assessed
according to the Thrombolysis In Myocardial Inf-
arction (TIMI) scale. Bare metal stents were im-
planted in all patients. The optimal direct effect of
the intervention was assigned when no residual ste-
nosis, or a stenosis of less than 20% of the refe-
rence segment diameter, was observed. Detailed
characteristics of the procedures are displayed in
Table 2.
Measurement of platelet aggregation
Blood samples were collected into hirudin-con-
taining tubes at 6.00 a.m., 10.00 a.m., 2.00 p.m., and
7.00 p.m. on the fourth and eighth days of hospital-
ization. The fourth day of hospitalization was cho-
sen because at this time the patient with acute cor-
onary syndrome is usually mobile, has usually left
the coronary care unit, and both aspirin and clopi-
dogrel fully exert their antiplatelet properties. The
eighth day (fourth day after introducing pantopra-
zole therapy) was chosen because it was assumed
that four days are enough to stabilize interaction of
pantoprazole and antiplatelet agents, if any such
interactions exist. If a patient was admitted after
7.00 p.m., the following day was counted as the first
day of hospital stay.
Table 1. Clinical characteristics of the study population.
Whole population Patients initially Patients initially
(n = 31)  treated with treated without
pantoprazole pantoprazole
(n = 15) (n = 16)
Age (years) 60.0 (53.0–68.0) 60.0 (57.0–65.0) 60.5 (53.0–69.0)
Gender [male/female] 22/9 10/5 12/4
Final clinical diagnosis:
UA 1 1 0
NSTEMI 2 0 2
STEMI 28 14 14
Time from symptom onset [h] 3.5 (2.0–7.0) 4.2 (2.0–7.0) 3.1 (1.5–6.3)
CK-max [U/L] 215.0 (73.0–1178.0) 192.0 (68.0–1050.0) 230.0 (75.0–1255.0)
CK-MBmax [U/L] 34.0 (16.0–182.0) 31.0 (14.0–175.0) 38.0 (18.0–210.0)
TnImax [ng/mL] 1.993 (0.690–31.200) 1.788 (0.548–28.700) 2.243 (0.815–36.500)
LVEF (%) 48.0 (40.0–50.0) 46.0 (40.0–50.0) 49.0 (42.0–51.0)
Risk factors of coronary artery disease:
Body mass index [kg/m2] 27.2 (25.6–29.8) 27.3 (26.9–29.4) 26.8 (25.0–30.7)
Arterial hypertension 22 10 12
Diabetes mellitus 13 including 7 including 6 including
10 newly diagnosed 5 newly diagnosed 5 newly diagnosed
patients   patients patients
Current smokers 15 8 7
History of smoking 4 2 2
Positive family history 4 2 2
Total cholesterol [mg/dL] 216.0 (192.0–244.0) 216.0 (200.0–234.0) 216.5 (189.0–244.0)
LDL cholesterol [mg/dL] 148.0 (125.0–175.0) 148.0 (122.0–161.0) 148.0 (129.0–175.0)
HDL cholesterol [mg/dL] 39.0 (34.0–41.0) 39.0 (36.0–42.0) 39.0 (31.0–41.0)
Triglycerides [mg/dL] 132.0 (86.0–112.0) 140.0 (86.0–211.0) 120.0 (74.0–193.0)
No statistically significant differences between both arms of the study group were observed; UA — unstable angina; STEMI — ST elevation myocar-
dial infarction; NSTEMI — non-ST elevation myocardial infarction
539
Michał Kasprzak et al., Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin
www.cardiologyjournal.org
Aggregation in the whole blood was assessed
within two hours of the venipuncture on a new gen-
eration impedance analyzer with multiple electrode
aggregometry according to the manufacturer’s in-
structions [21]. This method can detect the effect
of antiplatelet treatment and its results correlate
well with light transmission aggregometry [22]. The
whole procedure of platelet aggregation measure-
ment with a Multiplate® device (Dynabyte, Munich,
Germany) was performed in approximately ten
Table 2. Angiographic and procedural characteristics of the study population (n = 31).
Whole population Patients initially Patients initially
(n = 31)  treated with treated without
pantoprazole pantoprazole
(n = 15) (n = 16)
Coronary artery disease:
Single-vessel 11 6 5
Multivessel 20 9 11
Localization of culprit lesion:
Left anterior descending artery 12 6 6
Diagonal branch 1 0 1
Intermediate artery 1 0 1
Circumflex artery 4 2 2
Obtuse marginal artery 2 2 0
Right coronary artery 11 5 6
Baseline blood flow in the culprit vessel:
TIMI 0 16 9 7
TIMI 1 3 1 2
TIMI 2 2 0 2
TIMI 3 10 5 5
Final blood flow in the culprit vessel:
TIMI 2 2 1 1
TIMI 3 29 14 15
Usage of abciximab 8 3 5
Direct stenting 9 5 4
Multivessel primary PCI 9 3 6
Number of implanted stents:
0 2 1 1
1 16 7 9
2 6 3 3
3 6 4 2
4 1 0 1
Total length of implanted stents [mm] 18.0 (13.0–25.0) 19.0 (15.0–25.0) 15.0 (12.0–28.0)
Maximal stent or balloon diameter [mm] 3.0 (2.5–4.0) 3.0 (2.5–3.0) 3.2 (2.5–4.0)
Maximal inflation pressure [atm] 18.0 (16.0–22.0) 20.0 (18.0–22.0) 17.0 (14.0–18.0)
Outcome of primary PCI
Effective 31 15 16
Ineffective 0 0 0
Revascularization:
Complete 23 10 13
Incomplete 8 5 3
Qualification for further treatment:
Conservative 26 12 14
PCI 5 3 2
No statistically significant differences between both arms of the study group were observed; PCI — percutaneous coronary intervention
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minutes. Whole blood, which was utilized in our
study, is the physiological environment where
platelet function takes place in vivo. Moreover, the
use of whole blood for in vitro testing eliminates the
need for the time-consuming centrifugation steps
required to obtain the platelet-rich plasma neces-
sary for light transmission aggregometry. There-
fore, it must be stressed that impedance aggregom-
etry and light transmission aggregometry measure
different aspects of platelet function.
Impedance aggregometry results reflect inter-
actions between platelets and red and white cells,
while light transmission aggregometry does not [23].
The principle of impedance aggregometry is
based on the fact that platelets get sticky upon ac-
tivation, and therefore have a tendency to adhere
and aggregate on metal sensor wires in the test cell.
One Multiplate® test cell incorporates two inde-
pendent sensor units, each consisting of two silver-
coated, highly conductive wires. When activated
platelets adhere to the sensor wires, the electrical
resistance between the wires rises, which is con-
tinuously registered. The instrument detects the
impedance change of each sensor separately and
transforms it into arbitrary aggregation units (AU)
that are plotted against time. The area under the
aggregation curve (AUC) is an estimator of plate-
let aggregation that was evaluated in our study. It
is affected by the total height of the aggregation
curve as well as by its slope, and is best suited to
express the overall platelet activity. Aggregation,
quantified as the area under the curve, is displayed
in arbitrary units (10 AU ¥ min = 1 U). In previous
studies AUC highlighted as the parameter with the
highest diagnostic power [21, 24]. To assess a plate-
let response to aspirin we applied ASPI test (Dyna-
byte, Munich, Germany) which uses arachidonic
acid that serves as the substrate of the cyclooxy-
genase for synthesis of a potent platelet agonist,
thromboxane A2. Using this fast and standardized
method, comprehensive information on platelet
function and antiplatelet therapy can be obtained.
Reported intra-assay coefficient of variations (CV)
for ASPI test was 11.5%, while intra-individual CV
was 11.4% [23]. The manufacturer recommends
30 U as the cut-off value associated with platelet
hyperaggregability in patients on aspirin therapy.
Statistical analysis
Use of the Shapiro-Wilk test demonstrated that
the investigated variables were not normally dis-
tributed. Therefore, continuous results were re-
ported as median values and interquartile ranges.
Comparisons between groups were analyzed with
the Mann-Whitney unpaired rank sum test, where-
as the Wilcoxon matched-paired rank sum test was
used for comparisons within groups. A value of
p < 0.05 was considered statistically significant. All
computations were carried out with Statistica, ver-
sion 8.0 (StatSoft, Tulsa, USA).
Results
The two arms of the study group did not differ
in terms of clinical characteristics and angiographic
features (Table 1, 2).
The comparison of overall circadian arachidonic
acid-dependent platelet aggregation in patients with
ACS on dual antiplatelet therapy revealed substan-
tial, statistically significant, lower platelet aggrega-
tion in patients treated with pantoprazole (p < 0.03)
(Fig. 2). The tendency towards lower aggregation
ability in a group treated with pantoprazole was
preserved when the aggregation of platelets was
analyzed separately at different times (Fig. 3).
These differences, however, reached the point of
statistical significance only at 2.00 p.m. (4 U vs. 10 U;
p < 0.04). The highest absolute difference in
arachidonic acid-dependent aggregation between
patients treated with pantoprazole and the control
group was observed at 10.00 a.m: two hours after
administration of PPI along with both antiplatelet
agents (10 U vs. 19 U; p = 0.10).
Detailed comparisons of arachidonic acid-depen-
dent platelet aggregation between both arms of the
study group revealed lower values of platelet reactiv-
ity on Day 8 in pantoprazole treated patients; that
reached statistical significance at 10.00 a.m. (Table 3).
Figure 2. Comparison of overall (obtained from four daily
measurements) circadian arachidonic acid-dependent
platelet aggregation in patients on dual antiplatelet
therapy treated with and without pantoprazole.
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15.5% of ASPI results of patients treated with
pantoprazole and 17.7% of results in the control
group were above the cut-off values that, accord-
ing to the producer, may be associated with aspirin
resistance.
Discussion
The present study provided us with unexpect-
ed results. Previous animal trials had reported di-
minished effectiveness of ASA in co-administration
with antisecretory agents when a non-enteric-coat-
ed formulation of aspirin was used [19, 20, 25]. To
the best of our knowledge, this is the first up-to-
date study investigating the influence of PPI on
antiplatelet effect of enteric-coated formulations of
aspirin. We conclude that enteric-coating, altering
the pharmacokinetics of drugs, may be a reason for
the discrepancy between our study and earlier con-
ducted trials.
Plain aspirin is a weakly acidic drug (pKa =
= 3.5). It crosses the mucosa of the gastroduodenal
epithelium in its lipophilic state. To a lesser extent
it is transported through the upper part of the in-
testine where it can be absorbed despite alkaline
environment in its ionized form [26]. Soluble forms
of aspirin achieve peak blood concentrations 30 to
40 minutes after ingestion [26]. Its bioavailability
is approximately 50% [27]. Aspirin is partly hydro-
lyzed by abundant mucosal esterases to salicylic
acid (SA), and it is inactive in antiplatelet matter
metabolite [20, 28]. Hydrolyzation of ASA to SA in
gastrointestinal tract occurs mainly in the intestine,
and to a lesser extent in the stomach, where in nor-
Figure 3. Comparison of arachidonic acid-dependent
platelet aggregation at different times in patients on
dual antiplatelet therapy treated with and without pan-
toprazole.
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mal conditions esterases are less active due to low-
er pH. Giraud et al. [20] reported that elevated gas-
tric pH was related to substantially lower ASA con-
centration in the peripheral blood sample when con-
centrations of SA remains unchanged.
Enteric-coated preparations are created to by-
pass the stomach and prescribed in an attempt to
reduce gastrointestinal side effects [29]. They de-
liver ASA into the neutral pH environment of the
small intestine. In such an environment, the absorp-
tion of aspirin is delayed, with peak plasma concen-
trations achieved three to four hours after oral ad-
ministration, with reduced bioavailability [26, 30, 31].
Most studies indicate that some subjects treated
with low-dose enteric-coated (EC) aspirin fail to
achieve minimum thresholds of effective platelet
inhibition. Maree et al. [30] found that EC ASA is
less effective than plain aspirin in patients with
stable cardiovascular disease in terms of laborato-
ry measurements. Similarly, Alberts et al. [32], in
a study of patients with cerebrovascular disease, ob-
served normal platelet function despite ASA treat-
ment in a substantially higher percentage of patients
when enteric-coated formulations were used. Cox
et al. [31] assumed that 75 mg of enteric-coated as-
pirin delivers a dose of equivalent to 50 mg of plain
aspirin in healthy subjects which may predispose
to incomplete inhibition of COX in some (especial-
ly heavier) individuals.
The concomitant use of PPIs for gastrointesti-
nal protection may also interfere with the therapeu-
tic action of aspirin. Acid suppression with PPI di-
minishes the gastric aspirin absorption because
ASA is not absorbed into the stomach when its pH
is greater than 6.5. At pH 3.5–6.5 gastric absorp-
tion is lower than in the small intestine where ASA
can be absorbed to an appreciable extent in its ion-
ized form [33]. Rising gastric pH can also increase
the potential for mucosal esterases to hydrolyze
ASA to its inactive SA form [25]. Similarly, as with
enteric-coating formulations, this mechanism may
be crucial when aspirin is used at low doses in the
prophylaxis of stroke or coronary heart disease [20].
Lichtenberg et al. [19] showed that not only PPIs
but also ranitidine or cimetidine to a similar extent
attenuate antipyretic activity of aspirin in rats [20].
It supports the theory that increased gastric pH is
the main reason for reduced aspirin bioavailability
when PPI is co-administered. A human study con-
ducted on healthy subjects with ranitidine by Lev
et al. [34] reached similar conclusions. On the oth-
er hand, Inarrea et al. [35] in a study similarly de-
signed to ours but using plain aspirin and healthy
volunteers, found no differences in platelet lumiag-
gregation and skin bleeding time when low dose
aspirin was co-administered with omeprazole. It
should however be emphasized that in this study
only 14 subjects were enrolled and a tendency to
lower plasma ASA concentration on therapy with
pantoprazole was observed. As shown above, oth-
er antacids similarly to PPIs, lower the effect of as-
pirin. Hence, it is likely that interaction between
PPI and aspirin is a pharmacokinetic change, as dis-
cussed above, rather than any pharmacodynamic
interaction.
In clinical use there are myriad ASA formula-
tions including various enteric-coated preparations.
The outer sheet of EC ASA, used in our study, is
composed mainly of methacrylic acid (MAA) which
is one of the commonly used substances in the pro-
duction of enteric-coated drug formulations world-
wide. Methacrylic acid is stable in acid solutions.
Active substances are released from EC formula-
tions when in pH > 5.5. This means that, in normal
conditions, these drugs pass intact through the
upper gastrointestinal tract and do not release their
active substances until they reach the duodenum
or a more distal part of the intestines.
In our study we found higher antiplatelet po-
tential of low-dose methacrylic acid EC ASA when
it was co-administered with pantoprazole.
The likeliest explanation, in the light of earli-
er quoted studies, is better bioavailability of meth-
acrylic acid EC preparation in alkalized gastric juice.
As pH > 5.5 does not normally exist in the stom-
ach, addition of PPI causes earlier destabilization
of the methacrylic acid sheath. If gastric pH stays
between 5.5 (needed for the methacrylic acid sheath
to dissolve) and 6.5 (the pH limit for gastric ASA
absorption) aspirin, at least to some extent, may be
assimilated in the stomach. However, gastric pH,
obtained due to co-administration of pantoprazole
might be higher. In this case, the explanation of our
observation might be that, after sheath depolymer-
ization, aspirin reached the duodenum already in its
soluble form, thus assuring rapid absorption. This
possible mechanism may be supported by the fact
that the highest (though not statistically significant)
difference in medians of arachidonic acid-dependent
platelet aggregation was found at two hours after
morning tablets ingestion. This timing is between
the period needed for plain aspirin (30–40 min) and
EC formulations (3–4 h) to reach top plasma con-
centrations. Significant difference in medians of
arachidonic acid-dependent platelet aggregation at
four hours after ingestion suggests that pantopra-
zole does not only accelerate absorption but also
enhances the overall bioavailability.
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A potential limitation of our study is the fact
that we have not ultimately proven that observed
differences in aggregation are due to changed ab-
sorption. The confirmation would be direct meas-
urements of blood ASA concentrations at different
time points (30, 60, 120, 240 min) after oral admin-
istration of soluble vs. enteric-coated ASA, in co-
administration with PPI. However, as shown in pre-
vious studies, plasma half-life of ASA is relatively
short (about 15 min) because after absorption it is
rapidly hydrolyzed to inactive salicylic acid by es-
terases in the erythrocytes of the portal circulation
and in the liver [36]. For that reason, the main ef-
fect of ASA in acetylating platelet COX-1 is restrict-
ed to the portal circulation and the antiplatelet ef-
fect of aspirin may not correspond to its systemic
concentrations [25]. Another approach to support
our theory could be measuring platelet aggregation
one hour after drugs ingestion.
A second shortcoming is that although we per-
formed a crossover designed study to exclude im-
pact of acute phase of ACS, there was no washout
period after usage of pantoprazole in the first
16 enrolled patients. Also, the periods with and with-
out concomitant pantoprazole treatment were rela-
tively short (four days). However, this design meant
we could conduct the whole study during the hospital
stay, assuring 100% adherence to the therapy.
Our findings seem to agree with recent guide-
lines which recommend combining ASA and PPIs
instead of switching to clopidogrel in high risk gas-
trointestinal bleeding patients. The same recom-
mendations promote broad PPI gastroprotection for
patients receiving dual antiplatelet therapy [15]. In
our opinion, however, these guidelines should be
applied carefully since this approach may potentially
diminish the antiplatelet effect of clopidogrel be-
cause interactions between clopidogrel and PPIs are
not fully recognized [37–42].
Conclusions
To conclude, co-administration of pantoprazole
may enhance the antiplatelet effect of enteric-coat-
ed aspirin in patients with ACS undergoing PCI. To
recommend pantoprazole use in all patients receiv-
ing dual antiplatelet therapy, its potential negative
interaction with clopidogrel would have to be ulti-
mately excluded.
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